Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Perioperative prophylaxis,Treatment of respiratory tract infections,Urinary tract infections (UTIs),Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
1-2 g IV every 8 hours for moderate to severe infections; 2 g IV every 6-8 hours for life-threatening infections.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
1.8 hours (normal renal function); prolonged to 10-12 hours in ESRD; clinical context: dosing interval adjustment required for Cr Cl <55 m L/min
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Cefazolin is not significantly metabolized; it is primarily excreted unchanged in the urine via renal tubular secretion and glomerular filtration.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary (minimal, <1%); fecal (<1%)
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
80-86% bound to albumin
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
0.12-0.14 L/kg; clinical meaning: low Vd indicates limited extravascular distribution, primarily confined to extracellular fluid
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
IM: nearly 100%
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Cr Cl 30-60 m L/min: 1-2 g every 12 hours; Cr Cl 10-29 m L/min: 1-2 g every 24 hours; Cr Cl <10 m L/min: 1-2 g every 48 hours.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
No dose adjustment required for hepatic impairment; dose based on renal function.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
50-100 mg/kg/day IV divided every 8 hours; for severe infections up to 100 mg/kg/day divided every 6-8 hours; maximum 6 g/day.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
Initial dosing based on renal function; monitor Cr Cl and adjust per renal guidelines; age-related decline in renal function necessitates careful dose calculation.
None.
None.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity reactions including anaphylaxis,Clostridium difficile-associated diarrhea,Renal impairment requiring dose adjustment,Coagulation abnormalities (prolonged prothrombin time),Superinfection with resistant organisms
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
Hypersensitivity to cefazolin or other cephalosporins,Hypersensitivity to penicillins (potential cross-sensitivity)
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No significant food interactions. No dietary restrictions required. May be administered without regard to meals.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Cefazolin is pregnancy category B. No evidence of teratogenicity in animal studies; however, adequate human studies are lacking. Use in first trimester generally avoided unless clearly needed. No known fetal risks in second and third trimesters.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio ~0.03). Considered compatible with breastfeeding; potential for infant gut flora alteration and diarrhea. Minimal risk to nursing infant.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Increased renal clearance in pregnancy may require higher doses (e.g., 1-2 g every 6-8 hours) compared to non-pregnant adults. Monitor for therapeutic efficacy.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
First-generation cephalosporin; ensure renal dose adjustment in Cr Cl < 55 m L/min; use for surgical prophylaxis within 60 minutes prior to incision; no cross-allergy absolute with penicillins (approx 5-10% risk); monitor for Clostridioides difficile diarrhea.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
This medication is an antibiotic given intravenously (IV) to treat or prevent bacterial infections.,Inform your healthcare provider if you have any allergies, especially to penicillins or cephalosporins.,Report any signs of allergic reaction: rash, itching, swelling, difficulty breathing.,Take the full course of therapy as prescribed; do not stop early even if you feel better.,Notify your doctor if you develop severe diarrhea, especially if watery or bloody.,This product contains sodium; consult your doctor if you are on a sodium-restricted diet.
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE vs ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. The standard adult dose of ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 g IV every 8 hours for moderate to severe infections; 2 g IV every 6-8 hours for life-threatening infections.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE and ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cefazolin is pregnancy category B. No evidence of teratogenicity in animal studies; however, adequate human studies are lacking. Use in first trimester generally avoided unless cle. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.